Introduction
The right to health is associated with free access to essential medicines. However, according to the World Health Report 2000, around one-third of the world's population still lacks access to essential medicines (World Health Organization 2000) .
In China, the total expenditure on health care in 2007 was 4.81% of GDP (Ministry of Health 2007) , just under the 5% level recommended by the World Health Organization (WHO), with a sharp increase in household expenditure on health care, especially for those paying out of pocket (Wang and Dong 2007) . In 2007 total health expenditure in China reached 984.3 billion yuan (US$130.9 billion), with out-of-pocket health expenditure of nearly 485.3 billion yuan (US$64.5 billion) (Ministry of Health 2008a) . Although some health policies have been formulated to tackle the high level of medical costs (such as standardizing medical care services, bulk procurement of essential medicines and reduction of medicine prices by the National Development and Reform Commission and Ministry of Health), the high cost of medical care services and medicines is still considered to be the major obstacle in accessing health care in China .
In 2003, WHO and Health Action International (HAI) published a manual describing a standard methodology for measuring medicine prices (World Health Organization, Health Action International 2003) , in order to help decisionmakers clearly recognize purchasing prices and detect any major problems within their policies. Two surveys have been performed and used this methodology in both Shandong (Sun 2004) and Shanghai (Ye 2006) , and both revealed discouraging results about the availability and affordability of essential medicines. In order to get a clear picture of medicine prices in developing areas of China, a field survey was conducted in Hubei Province from 8 October to 7 November 2007 utilizing the WHO/HAI methodology.
Methods Sampling
Hubei Province is located in the centre of China, with a population of 60.7 million (approximately 46.5 million in rural areas in 2007), residing in 17 municipalities and 99 counties. The total output value (GDP) of the province is 915 billion yuan (approximately US$131 billion). The province consists of mountainous areas, hills and plains extending between its western and eastern borders. The mountainous areas are characterized by inconvenient transport routes, dispersed population, undeveloped economy, etc. To collect the required data, a stratified sampling method was used due to the complex terrain of the human, material and financial resources. Samples from Wuhan (provincial capital), Xiaogan and Enshi (see Appendix Table A1 ) in Hubei Province were chosen and surveyed. Eighteen public and 18 private essential medicines outlets were surveyed in each city, as detailed in Appendix  Table A2 .
Medicines surveyed
In the survey, 39 medicines were chosen according to the methods of WHO/HAI. Sixteen of these 39 belonged to the core list (medicines that cover most of the global disease burden 1 and are suggested by WHO/HAI for international comparison), and 23 were added as a supplementary medicine list (eight of these are from the core medicines list but in different doses) (see Appendix Table A3 ). The criteria for choosing the supplementary list were prepared based on the local disease burden and local needs (determined by a pilot survey), medicine supply, distribution system, dosage forms (according to the National Essential Medicines list), the opinions of several groups of experts 2 and a literature review.
The availability of medicines and their prices were assessed within the public (hospitals) and the private sectors (pharmacies). Data were collected by trained pharmacy students and supervised by the survey manager and the principal investigator. All the collected and completed forms containing data on medicine prices were checked on a daily basis. If any important information was missing, a follow-up telephone call was placed to obtain the remaining information. Prior to data collection, the principal investigator contacted the directors of health institutions in both sectors in order to ensure good cooperation between the staff and the team of researchers. For each medicine, data were collected based on the price and availability of innovator brand medicines and lowest-price generic equivalents (hereafter LPGs or generics in the text). In the public sector, both the procurement prices and the retail prices for patients were collected, while in the private sector only retail prices for patients were collected (collecting procurement prices can be a difficult task in these institutions due to privacy matters). Finally, medicine prices were transformed into unit prices 3 and recorded carefully on the day of data collection.
Statistical analysis
Upon finishing the field survey, a double input of data into the International Medicines Price Workbook software was done in order to reduce errors, and the Workbook's auto checker was used in the verification process (WHO/HAI 2003) . The workbooks will be submitted to HAI for posting on the HAI database after this paper is published.
Availability evaluation and criteria within our study The availability of each medicine is reported as 'the percentage of stock availability of the required medicines in the facilities on the day of data collection' (WHO/HAI 2003). The following criteria were used to describe the availability of medicines:
Absent, 0% of facilities: these medicines were not found in any facility surveyed; Low, <50% of facilities: these medicines were hard to find; Fairly high, 50-80% of facilities: these medicines were available in many facilities; High, >80% of facilities: good availability. Gelders et al. (2006) studied surveys of the prices, availability and affordability of 14 chronic disease medicines in 30 countries (each using the WHO/HAI methodology), but their criteria did not contain an 'absent' category as in our study. Thus, this category will provide more evidence for policy makers.
Price criteria and evaluation within our study The median price ratio (MPR) for each medicine was calculated using the Workbook developed by WHO/HAI only if the medicine was available in at least one facility. There were no strict rules to interpret retail MPRs, since many factors need to be considered before interpreting the MPR, such as market size and penetration, competition and therapeutic alternatives, consumption, economic scales, national wealth and wealth distribution, health system structure and accessibility, distribution and storage charges, local taxation and regulation. However, according to the WHO/HAI methodology, if an MPR is twice the international reference price for a generic equivalent product (considered a warning level), 6 then this should be a cause for concern since the price is likely unaffordable (Gelders et al. 2006) .
Assessment of affordability
In accordance with the WHO/HAI methodology, affordability was assessed by calculating the number of days' income required for patients to purchase any of the selected 16 generic medicines for the 8 different designated types of disease; namely, 7 days' treatment for an acute condition or 30 days' treatment for a chronic condition. In general, treatments that cost 1 day's income or less were considered affordable. In contrast to the WHO/HAI methodology, which uses only the daily wage of an unskilled government worker to assess affordability, we selected two different income levels 7 to reflect ability to pay in the rural areas of Hubei Province. The two income levels are the national low-income line (i.e. the national poverty line, at 1067 yuan a year, or about US$0. 
Results

Availability of innovator brands and LPGs
For patients to be able to access treatments adequately, medicines must be available in the public and the private sectors. The median availability of all medicines surveyed in the public and the private sectors was 38.9% and 44.4% for LPGs, respectively. The results from the Workbook show that the availability was generally low (see Table 1 ). Ceftriaxone was excluded when the survey was undertaken in the private sector, because it was not available without prescription.
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Only nine types of innovator brand medicine were found in the public sector and six in the private sector. The low availability of innovator brands was unsurprising, since patients in rural areas cannot afford such expensive medicines. Therefore, innovator brand medicines were not the major concern in the rural areas, but rather the LPGs.
Only 13 LPGs in the public sector and 18 in the private sector had >50% availability. Some LPGs, such as beclomethasone, losartan and fluoxetine, were absent from both public and private sectors. In addition, low availability of oral hypoglycemic medicines was also detected in both sectors, e.g. Metformin and Glibenclamide. Only captopril and amoxicillin were commonly available in both sectors. Furthermore, no health institution in the private sector was able to offer diazepam 5 mg tablets, amlodipine 5 mg tablets, metformin 500 mg tablets or amitriptyline 25 mg tablets (see Table 1 ).
Price
Comparison of procurement prices between innovator brands and LPGs
The data collected on procurement prices of surveyed LPGs are generally favourable. The median MPRs of 25 LPGs were 0.74 times the international reference prices, while for 7 innovator brands the median MPRs were 9.78 times the international reference prices (see Table 2 ). Furthermore, the median MPRs of LPGs in the core and supplementary lists were 0.73 and 0.81, respectively. As for all the medicines surveyed, there was wide variation in the MPRs of LPGs (0.07-18.38). Sixteen of the 25 LPGs were procured at lower prices than the international reference prices; however, five medicines were more than twice the reference price, and hence above the affordability warning line.
Comparison of retail prices between innovator brands and LPGs
For retail prices in the public sector, the seven innovator brands illustrated a wider range and a higher median value (range 2.35-35.88; median 11.25) than the 25 LPGs (range 0.09-22.05; median 1.04) (see Table 2 ). In the core and supplementary lists of LPGs, the median MPRs were 1.05 and 1.02 times the international reference prices, respectively. As shown in Appendix Table A4 , the majority of LPGs were under the acceptable price line, while eight medicines were above the warning level. The MPRs for some generics, such as Albendazole, Fluconazole and Amlodipine, were six times the international reference prices, and varied quite widely in the public health sector (see Appendix Table A4 ).
In the private sector, the MPR of five innovator brands was found to be 19.94 times the international reference prices (range 1.29-28.48), while for generics the median MPR of 20 LPGs was 0.68 times the international reference prices (range 0.08-2.82). Further analysis showed that the median MPR of core list generics was 0.51 times the international reference prices (range 0.23-2.82) and 0.78 for the supplementary list (0.08-2.45) ( Table 2 ). In Appendix Table A4 , only 3 out of 20 generics were above the warning level. Furthermore, comparing retail prices between both sectors, the median MPR of all generics in the public sector was higher than that in the private sector. For example, the MPR of salbutamol in the public sector was up to 5 times higher than in the private sector (see Appendix Table A4 ). In addition, some other generic medicines, such as albendazole, co-trimoxazole and fluconazole, were found at very high prices in both sectors.
Mark-up rates from procurement to retail prices in the public sector Prices of drugs in the public sector showed wide variation. To investigate the reasons for this, we performed an analysis of mark-up rates to reveal whether the variation was related to high procurement pricing or to high add-on costs, or to a combination of both.
There were great differences in mark-up rates (median markup rate: 44.8%; range: 15.6-177.8%; see Appendix Table A5 ), and generally rates decreased with increasing procurement price. For generic medicines with procurement prices lower than the international reference prices, the median mark-up rate was 53.9%, as shown in Appendix Table A5 (177.8% for Diclofenac was the highest). For generic medicines with procurement prices higher than the international reference prices (such as omeprazole, co-trimoxazole, amitriptyline), the median mark-up rate was 38.5%. However, the actual mark-up amounts of medicines with prices lower than the international reference prices were less than the generic medicines with prices higher than the international reference prices (median mark-up cost: 0.22 vs. 0.73). Therefore, high retail prices were mainly attributable to high procurement prices (the higher the procurement price, the more a hospital could add on as a mark-up).
Affordability at different economic levels
The affordability of treatments for eight different health conditions is listed in Table 3 (affordability of innovator brands was not a major concern because their availability was more limited). Expenditure on medicines for these conditions is acceptable for people with an average economic level, but for those with a low income level it is unaffordable. Considering LPGs, expenditure on most treatments was less than 1 day's income, at an average income level, for both acute and chronic diseases, except for lovastatin, omeprazole, compound aluminum hydroxide and salbutamol (Table 3 ). In contrast, the lowincome population would pay more than 1 day's income for half of these medicines, with the situation being worse in the public than in the private sector. The cost of 1 month's treatment with generic lovastatin requires about 10 days' income in the public sector, while the total treatment of Salbutamol costs almost 8.8 days' income.
Comprehensive analysis of LPG availability and price Figure 1 depicts the availability and price of LPGs within the public sector. For generics located in the 4th quadrant, patients have good access, e.g. Catopril has 88.9% availability and a MPR of 0.26. For generics in the 1st quadrant, patients not only have to bear the unaffordable cost of the medicine, but also most probably are not able to attain them from a nearby hospital or pharmacy. For example, amlodipine was available only in 16.7% of surveyed public sector hospitals and at over 22 times the international reference price. Compared with the public sector, Figure 2 shows the more positive situation in the private sector. Eleven medicines are in the 4th quadrant, with good access, and only two medicines (co-trimoxazole and Albendazole) are located in the 1st quadrant, with low availability and high prices. Overall, in both the public and the private sectors, patients could purchase a number of generics at reasonable and affordable prices and with wide availability, most notably captopril, amoxicillin, ranitidine, nifedipine, metronidazole and aminophylline.
Discussion
Due to its reliability and practicality, the WHO/HAI methodology has already been utilized in >40 surveys (Saleh 2005; Mendis 2007 ). This is the first study to apply this methodology to middle-income rural areas in central China, giving a picture of the availability, affordability and accessibility of essential medicines. In addition, the results of this study can be compared with the two previous surveys performed in Shandong and Shanghai in order to obtain a more precise evaluation of the availability of medicines in China.
This study chiefly compared the prices, availability and affordability of medicines, and also aggregated selected medicines for valid comparisons. One particularly important aspect of this study is that we included an analysis of the markup costs from procurement prices to retail prices in the public sector, instead of undertaking a price component analysis, since mark-up rates are a major concern in China.
In early 2009 China embarked on a reform of the health care system. This reform encompasses four key parts, one of which is recognizing the National Essential Medicines Scheme (NEMS) as the basic supply system for medications, to ensure safety, quality and supply. The other three foci of the reform are the public health service, medical treatment services and medical insurance. This article should be useful to government health policy makers in providing a broad picture of the present situation regarding essential medicines and suggesting ways to 
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strengthen the NEMS and hence bring benefits to patients. For example, a continuous monitoring system would be useful for supervising and controlling the availability of essential medicines for the population.
Availability of different types of medicines
There was greater availability of generic medicines than innovator brands in the public and private sectors. Low availability of medicines listed on the National Essential Drug List was found in both sectors (State Food and Drug Administration of China 2004), but was worse in the public than the private sector. The availability of some medicines for common illnesses such as diabetes and psychosis was extremely low in both sectors. The reasons for this could be attributed to prescribers who are inclined to select other alternatives due to the high price of certain specific medicines (e.g. Lovastatin) or to doctors choosing to prescribe medications not included in the essential medicines list (e.g. glipizide and isosorbide mononitrate). Basic health care among psychotic and diabetic patients is of low priority (Zhang et al. 1998) , as illustrated by the poor availability of the corresponding medicines in both sectors. Furthermore, the very low availability of medications for these conditions in rural areas can also likely be attributed to a lack of awareness among patients concerning these diseases.
Some medicines, such as metformin, amlodipine, diazepam and amitriptyline, are found only occasionally in the public sector and are absent in the private sector, which will have direct implications on patients' access to them. In contrast, availability of medicines in the private sector for common conditions such as infection, fever and hypertension was satisfactory.
The difference in the availability of oral formulations between the public and private sectors was not surprising. In the public sector, injections have always been chosen first rather than the oral formulations, because they provide not only rapid curative effects but also economic benefits . 8 For example, aciclovir injection was used frequently in the public sector instead of the oral formulation. It is worth pointing out that the low availability should not be overemphasized, since strengths or dosage forms of a medicine Figure 1 Comprehensive analysis of medicine availability and retail price in the public sector (LPGs) other than those specified in the WHO/HAI guidelines might be available; 9 for example, only Diazepam 5 mg and Ciprofloxacin 250 mg were found in the field survey. Also, during implementation of this survey, availability was measured by collecting data at one point in time only from any health facility. However, low availability of medicines is not limited to primary health care facilities in Hubei province. Low availability was also observed in both the Shandong and the Shanghai studies. In the public sector, the median availability among the selected 15 LPGs extracted from the surveyed core list was only 16.7% in Hubei, 20% in Shandong (Sun 2005) and 20% in Shanghai (Ye 2006) . The median availability of the same medicines was also not encouraging in the private sector: 11.7% in Hubei, 25% in Shandong (Sun 2005) and 10% in Shanghai (Ye 2006) , respectively.
Prices
The Central Public Bidding Procurement for the public sector was launched in 2000 by the Ministry of Health. The MPR of procurement prices for LPGs, at 74% of the MSH international reference price, indicated efficient procurement. In comparison, the MPR for the innovator brands was 10 times the MSH reference price. Also, in the Shandong and Shanghai studies, the MPRs of procurement prices were 0.62 and 1.53 times the international reference prices for LPGs, respectively, and 6.30 and 6.7 for innovator brands. The data can be compared with India and Sri Lanka, as these countries were set as examples for efficient procurement and pricing. In the public sector, analyses of procurement prices within six Indian states showed that the median MPR of LPGs was lowest in Chennai (0.27) and highest in Rajasthan (0.68) (Kotwani 2004; Lakshmi Suresh 2004; Shoba 2004; Singal 2004; Archana et al. 2005; Tripathi et al. 2005) . Similarly in Sri Lanka, a MPR of 2.67 was reported for innovator brands and 0.82 for LPGs in the public procurement sector (Wickremasinghe 2006) .
For retail prices to patients in the public and the private sectors, the MPRs of 21 generic medicines available in both sectors were generally higher in the public sector (median 1.02 and 0.57 for public and private sector, respectively). This finding is similar to the studies in Shandong and Shanghai (core list: 0.77 and 1.68 for the public sector; 0.52 and 1.58 for the private sector, respectively) (Sun 2005; Ye 2006 ). Analyses in six Indian states revealed that the MPRs for generics in the core list were lower in the private sector than in the public sector, which ranged from 1.82 (Rajasthan) to 3.54 (West Bengal) (Kotwani 2004; Lakshmi Suresh 2004 ; Archana et al. 2005; Tripathi et al. 2005) . This might be a reason for the difference in health care systems between India and China.
Several reasons might explain the higher retail prices in hospitals. Firstly, cash-paid procurement might have led to a decrease in procurement prices for retail pharmacies (hospitals usually pay within 2 months or more to the pharmaceutical supplier). Secondly, when medicines are purchased from designated health facilities of the New Rural Cooperative Medical Scheme (NRCMS), 10 they are able to collect their rebates instantly. However, it is rare for the NRCMS to reimburse for medicines purchased from any retail pharmacies. Therefore, the retail pharmacies are forced to lower their prices to attract more patients. Lastly, the public sector plays the dominant role in the pharmaceutical supply chain in China. On one hand, the public hospitals tend to purchase medicines from the Central Public Bidding Procurement at high prices in order to make more from mark-ups since there is a legal 15% markup rate (the higher the medicine procurement prices, the more the public hospitals can add on). This is justified within the situation of insufficient government fiscal investment. However, on the other hand, hospitals do add on as much as possible to the price. In this survey, margins of 42% for the median mark-ups were found. The mark-ups of some medicines, such as diclofenac, diazepam and hydrochlorothiazide, even exceeded 100%. On average, in China 41.28% of the total institutions' revenue in the public sector comes from sales of medicines (Ministry of Health 2008b) . In order to regulate the prices of medicines in the public sector, aside from the Central Public Bidding Procurement, two other price control policies were launched: Maximum Retail Prices, in order to restrict prices for patients, and the Maximum Margins of Hospitals' Medicine Sales, to regulate the mark-up from procurement to patient prices (cannot exceed 15%). Unfortunately, these measures have not been as effective or influential as desired (Du and Zhang 2007) . To some extent, the results from this survey indicate that many of the rural health facilities are still generating their revenues through the sale of medicines, with a consequential impact on patients.
Affordability
In other WHO/HAI medicine price and availability surveys, affordability was measured by the number of days' wages needed to pay for treatment, taking the lowest paid government worker as the baseline. We chose not to follow this approach because in China, while the unskilled government worker receives a low wage, this wage is still considered to be a high income. Even the lowest paid government worker is still much better paid than most other workers. If the lowest paid government worker metric was adopted, it would not reflect the real situation of essential medicines' affordability for most of the rural population in China. Instead, we chose 'the national low income line' and 'the per capita net income of a farmer living in Hubei province', as levels that really reflect the situation of the poor and the average Hubei resident. By using these measures it was possible to show that affordability of medicines was generally not a problem for the average resident but would be a severe problem for a poor person, especially if they purchased their medicines from the public sector.
Study limitations
A particular weakness of this study is that availability was measured at 'one time' on the day of data collection from any health facility. Therefore, some facilities might usually have had a product in stock, but on the specific day of the survey it happened that they ran out of it.
Conclusion
The present survey shows that even though the public sector was procuring medicines at reasonable prices through the efficient Central Public Bidding Procurement, the mark-up rate was higher than it should be, the availability of essential medicines is very low, and patients could not be reimbursed from the NRCMS after purchasing medicines from retail pharmacies, indicating that access to essential medicines in the rural areas of China is still weak. Future surveys and policy interventions should focus on the public sector in order to guarantee that basic medical services are accessible, with sufficient fiscal investment, and making the pharmaceutical market more competitive. In conclusion, much more work could be done to improve the availability and affordability of essential medicines, and particularly to reduce prices in the public sector.
Endnotes
1 Global/regional burden of disease/prevalence patterns: used to treat common acute and chronic conditions that cause significant morbidity and mortality, including cardiovascular diseases, diabetes, asthma, respiratory tract infections and mental illness. 2 A group of doctors, academics and officials from the Ministry of Health. 3 Unit price refers to the price per individual tablet, capsule, millilitre (for injections, liquids, etc.), gramme (for creams, etc) or dose (for inhalers). 4 The median price ratio (MPR) is the median unit price of a medicine across the facilities surveyed divided by the median international reference price. We made an adjustment to the WHO/HAI methodology, which requires that data come from a minimum of four facilities. This adjustment was made due to the different strengths or dosage forms for particular medicines that are commonly used in China, and that differ from the WHO/HAI medicines. Some WHO/HAI medicines were hard to find in four facilities, but after the adjustment was performed, the results of this study remained comparable with other studies since most of the data were extracted from four facilities. 5 The international reference price is the median of recent procurement or tender prices offered by predominantly not-for-profit suppliers to developing countries for multi-source products. 6 In China, retail prices in private pharmacies have been found to be lower than in the public sector. Thus, any MPRs lower than 2, instead of 2.5 as defined by Gelders et al. (2006) , were considered to be acceptable. 7 We used two different economic levels because this would allow more in-depth analysis regarding the affordability of medicines, to see whether they are unaffordable for both the poorest and the average populations. 8 Usually injections are the most expensive and not available in pharmacies without a prescription. 9 See website: http://www.whocc.no/atcddd/. Doses for individual patients and patient groups will often differ from the Defined Daily Dose and will necessarily have to be based on individual characteristics (e.g. age and weight) and pharmacokinetic considerations. 10 The NRCMS is a medical cooperative security system implemented in the rural areas. 
